YORGANCIOĞLU, A. A. 2022. Short-acting β2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study. SABA overuse in asthma, is it still a burden? Where we stand in disease control and management .

YORGANCIOĞLU, A. A., (2022). Short-acting β2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study . SABA overuse in asthma, is it still a burden? Where we stand in disease control and management

YORGANCIOĞLU, AYŞE. "Short-acting β2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study," SABA overuse in asthma, is it still a burden? Where we stand in disease control and management, 2022

YORGANCIOĞLU, AYŞE A. . "Short-acting β2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study." SABA overuse in asthma, is it still a burden? Where we stand in disease control and management , 2022

YORGANCIOĞLU, A. A. (2022) . "Short-acting β2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study." SABA overuse in asthma, is it still a burden? Where we stand in disease control and management .

@conferencepaper{conferencepaper, author={AYŞE ARZU YORGANCIOĞLU}, title={Short-acting β2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study}, congress name={SABA overuse in asthma, is it still a burden? Where we stand in disease control and management}, city={}, country={}, year={2022}}